Interestingly, a combination of both, targeted and immunotherapy, appears to be the most promising approach at the moment and clinical trials are ongoing, combining vemurafenib and cobimetinib with atezolizumab, a monoclonal antibody against PD-L1 in melanoma [17]. This evidence concerns the gene CD274 and melanoma.